Merit Medical Systems, Inc. MMSI R2KR3KPHARMA

Q: What is the current share price of Merit Medical Systems, Inc. (MMSI)?

As of 2026-09-07 16:24 PDT, Merit Medical Systems, Inc. (MMSI) trades at $89.60 on NasdaqGS. Its 52-week range is $60.31 to $93.18.

Q: What is the market capitalisation of MMSI?

Merit Medical Systems, Inc. (MMSI) has a market capitalisation of $5.35B on NasdaqGS.

Q: What is the P/E ratio of MMSI?

MMSI trades at a trailing price-to-earnings (P/E) ratio of 36.87. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.27.

Q: What is the return on equity (ROE) of MMSI?

MMSI has a return on equity (ROE) of 9.19%. Its return on capital employed (ROCE) is 7.55%.

Q: Is MMSI a good stock to buy?

This page provides a data-driven analysis of Merit Medical Systems, Inc. (MMSI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Instruments & Supplies · United States

https://www.merit.com

Company Profile ↓

$89.60

+4.00% 1Y

Mkt Cap$5.35B

P/E36.87

P/B3.27

52W High$93.18

52W Low$60.31

Book Value$27.27

EPS (TTM)$2.43

Company Overview

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems. It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 11.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 11.7% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $1.52B (+11.8% YoY); net profit $128.49M.
Trailing 12 Months Year-on-year growth — revenue +9.5%, earnings +20.4%.
5-Year Trend Long-term compounding — revenue CAGR 11.7%, profit CAGR 11.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	11.72%
1 Year:	9.50%

Compounded Profit Growth

5 Years:	11.50%
1 Year:	20.40%

Stock Price Performance

1 Year:	+4.00%
6 Months:	+23.31%
3 Months:	+38.96%
1 Month:	+2.18%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 89% of range

$60.31 $93.18

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)58.63 · Neutral

Price Performance

1M+2.18%

3M+38.96%

6M+23.31%

1Y+4.00%

Valuation vs Sector

P/E of 36.87 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 11.7% over 5 years.
Profit CAGR of 11.5% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

36.87

Industry PE

25.17

Forward P/E

19.43

PEG Ratio

1.76

Book Value

$27.27

Price to Book

3.27

P/S

3.37

EV/EBITDA

16.78

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

11.72%

Profit 5Y

11.50%

Revenue (YoY)

9.50%

Earnings (YoY)

20.40%

Profitability & Returns

ROCE

7.55%

ROE

9.19%

ROA

4.92%

Profit Margin

9.22%

Op Margin

14.46%

Gross Margin

49.51%

EPS (Latest Qtr)

$0.65

EPS (TTM)

$2.43

Balance Sheet & Liquidity

Debt/Equity

0.49

Quick Ratio

2.64

Current Ratio

4.20

Debt

$820.12M

Total Assets

$2.86B

Current Assets

Working Capital

Ownership

Promoter Holding

2.43%

Chg in Prom Hold

-0.01%

FII / Inst Holding

108.22%

Chg in FII Hold

0.01%

Financial Snapshot

Enterprise Value

$5.35B

Total Revenue (TTM)

$1.58B

EBITDA

$338.94M

Free Cash Flow

$173.90M

Operating Cash Flow

$283.45M

Shares Outstanding

59.71M

Gross Margin

49.51%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	MMSI Merit Medical Systems, Inc. R2KR3KPHARMA	89.60	36.87	$5.35B	0.00%	7.55%	9.19%	11.72%	11.50%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	171.07M	186.55M	179.34M	190.90M	203.03M	224.81M	221.66M	233.25M	238.35M	255.53M	243.05M	257.92M	243.53M	218.37M	243.97M	258.00M	248.91M	280.32M	267.02M	275.42M	294.98M	287.18M	297.56M	320.06M	315.23M	323.51M	338.00M	339.85M	355.35M	382.46M	384.16M	381.88M	418.84M
Gross Profit	60.89M	59.20M	60.31M	60.10M	66.85M	67.81M	70.26M	75.94M	84.14M	80.51M	85.66M	88.06M	100.01M	102.04M	104.67M	104.64M	111.96M	104.14M	111.63M	103.78M	84.22M	102.01M	111.16M	111.89M	124.14M	120.49M	120.91M	135.07M	128.57M	138.36M	152.78M	142.20M	151.72M	161.10M	157.53M	172.02M	184.49M	186.41M	184.80M	215.17M
Operating Income	12.24M	8.55M	-	7.71M	11.58M	2.99M	12.60M	5.61M	13.36M	879.00K	13.22M	8.78M	15.11M	21.06M	13.66M	9.52M	12.20M	-2.88M	-3.41M	1.36M	-19.00M	64.00K	16.01M	14.19M	8.89M	15.93M	15.23M	23.26M	18.66M	26.38M	28.81M	35.14M	35.92M	45.95M	37.26M	41.03M	46.88M	42.61M	44.16M	60.40M
Net Income	7.40M	4.82M	6.41M	4.35M	7.29M	973.00K	7.51M	14.80M	9.48M	-3.57M	6.81M	5.27M	10.94M	16.62M	9.19M	6.20M	6.86M	-3.40M	-4.21M	-3.15M	-19.06M	-3.01M	15.38M	10.96M	4.92M	11.97M	10.54M	15.30M	15.27M	20.70M	20.25M	25.83M	28.24M	35.73M	28.44M	30.15M	32.58M	27.75M	40.99M	38.80M
Diluted EPS	0.17	0.11	0.14	0.10	0.16	0.02	0.17	0.32	0.19	-0.07	0.13	0.10	0.21	0.30	0.16	0.11	0.12	-0.06	-0.08	-0.06	-0.34	-0.05	0.27	0.19	0.09	0.21	0.18	0.27	0.27	0.36	0.35	0.44	0.48	0.61	0.48	0.49	0.54	0.46	0.68	0.65
R&D Expense	9.20M	10.52M	-	10.59M	11.43M	11.42M	-	12.53M	13.31M	12.84M	-	14.32M	15.32M	14.53M	-	16.04M	16.33M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	257.46M	296.75M	359.45M	394.29M	449.05M	509.69M	542.15M	603.84M	727.85M	882.75M	994.85M	963.88M	1.07B	1.15B	1.26B	1.36B	1.52B
Gross Profit	108.80M	128.50M	165.47M	181.99M	194.37M	225.22M	235.78M	265.02M	326.25M	394.77M	432.37M	401.18M	485.33M	519.10M	583.87M	643.33M	738.27M
Operating Income	32.85M	17.20M	33.19M	29.64M	27.84M	40.17M	37.54M	34.88M	33.07M	58.62M	15.43M	-1.56M	60.92M	87.56M	123.94M	155.69M	184.72M
Net Income	22.53M	12.46M	23.04M	19.71M	16.57M	22.97M	23.80M	20.12M	27.52M	42.02M	5.45M	-9.84M	48.45M	74.52M	94.41M	120.36M	128.49M
Diluted EPS	0.63	0.35	0.58	0.46	0.39	0.53	0.53	0.45	0.55	0.78	0.10	-0.18	0.84	1.29	1.62	2.03	2.13
R&D Expense	11.17M	15.34M	21.94M	27.80M	33.89M	36.63M	40.81M	45.23M	51.40M	59.53M	-	-	-	-	-	-	-

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	271.51M	369.48M	447.02M	705.31M	728.28M	747.16M	778.73M	942.80M	1.11B	1.62B	1.76B	1.66B	1.65B	1.66B	2.33B	2.42B	2.69B
Total Equity	194.31M	218.81M	235.62M	357.09M	381.58M	405.71M	435.26M	466.10M	498.19M	676.33M	932.77M	949.94M	958.58M	1.04B	1.14B	1.20B	1.38B	1.58B
Cash & Equivalents	34.03M	6.13M	3.73M	10.13M	9.72M	7.46M	7.36M	4.18M	19.17M	32.34M	67.36M	44.32M	56.92M	67.75M	58.41M	587.04M	376.71M	446.40M
Long Term Debt	-	-	81.54M	30.74M	227.57M	238.85M	214.49M	197.59M	314.37M	259.01M	373.15M	431.98M	343.72M	234.40M	186.76M	823.01M	729.55M	734.04M
Total Liabilities	-	-	133.87M	89.93M	323.73M	322.58M	311.91M	312.62M	444.61M	435.48M	687.24M	807.38M	705.82M	608.50M	519.57M	1.12B	1.04B	1.10B
Current Liabilities	-	-	40.18M	43.80M	73.00M	65.59M	75.43M	87.91M	88.33M	115.62M	175.34M	181.66M	185.00M	236.28M	220.65M	203.56M	216.40M	239.76M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	30.07M	34.76M	34.02M	46.94M	51.37M	53.33M	69.46M	53.60M	62.73M	86.53M	77.81M	165.27M	147.23M	114.29M	145.15M	220.80M	297.37M
Investing Cash Flow	-65.79M	-112.83M	-74.02M	-255.57M	-68.61M	-36.20M	-62.02M	-159.11M	-146.76M	-378.82M	-134.48M	-58.65M	-37.16M	-57.40M	-175.35M	-368.65M	-247.39M
Financing Cash Flow	7.82M	76.12M	46.70M	208.29M	14.77M	-16.97M	-10.23M	121.09M	96.52M	328.28M	33.53M	-95.71M	-98.44M	-60.26M	559.27M	-60.01M	16.00M
Capital Expenditure	-18.48M	-23.65M	-59.20M	-64.64M	-59.51M	-34.18M	-50.96M	-32.84M	-38.62M	-63.32M	-78.17M	-45.99M	-27.94M	-45.03M	-34.29M	-35.14M	-81.72M
Free Cash Flow	11.59M	11.11M	-25.18M	-17.70M	-8.13M	19.14M	18.50M	20.76M	24.10M	23.21M	-360.00K	119.28M	119.29M	69.26M	110.86M	185.66M	215.66M
Share Buybacks	2.47M	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	42.3%	43.3%	46.0%	46.2%	43.3%	44.2%	43.5%	43.9%	44.8%	44.7%	43.5%	41.6%	45.2%	45.1%	46.4%	47.4%	48.7%
Operating Margin %	12.8%	5.8%	9.2%	7.5%	6.2%	7.9%	6.9%	5.8%	4.5%	6.6%	1.6%	-0.2%	5.7%	7.6%	9.9%	11.5%	12.2%
Net Margin %	8.8%	4.2%	6.4%	5.0%	3.7%	4.5%	4.4%	3.3%	3.8%	4.8%	0.5%	-1.0%	4.5%	6.5%	7.5%	8.9%	8.5%
ROE %	10.3%	5.3%	6.5%	5.2%	4.1%	5.3%	5.1%	4.0%	4.1%	4.5%	0.6%	-1.0%	4.7%	6.5%	7.9%	8.7%	8.1%
ROCE %	-	5.2%	8.2%	4.7%	4.2%	6.0%	5.4%	4.1%	3.3%	4.1%	1.0%	-0.1%	4.3%	6.1%	5.8%	7.1%	7.6%

Shareholding Pattern

Insiders

2.43%

Institutions

108.22%

Public Float

110.91%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	15.85%	9.46M	$856.45M
2	Vanguard Portfolio Management LLC	5.82%	3.47M	$314.35M
3	Vanguard Capital Management LLC	4.34%	2.59M	$234.41M
4	State Street Corporation	4.14%	2.47M	$223.92M
5	Conestoga Capital Advisors, LLC	3.32%	1.98M	$179.15M
6	Geode Capital Management, LLC	2.72%	1.63M	$147.13M
7	Fuller & Thaler Asset Management Inc.	2.70%	1.61M	$145.96M
8	Dimensional Fund Advisors LP	2.44%	1.46M	$132.01M
9	Nomura Asset Management International Inc	2.14%	1.28M	$115.75M
10	Congress Asset Management Co	1.98%	1.18M	$107.17M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MMSI

Google News Sat, 05 Sep 2026

MMSI vs. WST: Which Stock Should Value Investors Buy Now? - Eastern Progress

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPYm13eTJPSWdpZnFpcmZ0ZmhoOFJnWlVBNzB0dllpakF1OVJYQXFZaFhtS2pnOUR6Y3JsWkxxWWtwYldxVzM4TTE0cFMxR3RIZFVObzZqMm5Sem1ucGp0a0ZBR2N1bEdyeGdrVy1hUzI4OW9Dem56Nkt4amNzOElYVXF1QUdTVUdGa3Yxc0…

Google News Fri, 04 Sep 2026

Merit Medical is scheduled for investor events in Boston, New York and online - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNbFYzTWlrb1E4U1MyOHE5Zl94WUh5OVJkZmVHbXJjTWk3T09DS2hNazR6NVptcXI0Rzk0WHp6WFNEcmpVUkdndF9LY3ZmMFhpZjdSVzk2aDM0eUwzOG8zQ1dyRkQwblE3ajk2TWh5Ri1NVjhFaFpxNEJaVHlYR05ib1NaRzQxV1prN1A5eT…

Google News Fri, 21 Aug 2026

COO vs. MMSI: Which Stock Is the Better Value Option? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQTHo3V2hnU3FTdVBGU3Zkb1ltMEl2SkpPdlhwMDEzTVg0YjMtUTZ1WHhnOFhJdGREUjZ1eGxianZXUGN1VjZyUFRkRzUxX3ZuMWJvZ201MlhQdmhGRnpkbVBMVmpzUm0xX3E2R0FTeXZyQWsyM2ZwNVp5RHFDVUZfdF9jLVA1SjBjamNwM3…

Google News Wed, 02 Sep 2026

Here's Why You Should Add Merit Medical Stock to Your Portfolio Now - TradingView

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOTFZBeHVqRHZpanpPRU4taEY0bnFWYllkMUJ3UjFpQ216dFc4d0VkVmhJcXgwUzh4cXc2WHZvTk9hdmxmOWwwTEQ5a3Y0X1ljQ2NPQk1OLUhXX1J6dHNCSXowem9wNkhiV2o2TGsxeWFoaVBZcFVGbE14Sld0UmtCR0hRQm1ZZE9oQ2o2RD…

Google News Mon, 17 Aug 2026

3 Overrated Stocks with Warning Signs - StockStory

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNT0Vkb2JVbXpJN1ZxLUxXcFFVWDhuRTVNSTFfSXZ1Mk93QVRlZUNaam91b1FiU0d0Ump5NkxRVDFOSnFGV0FWakZkMEpJYXdxRnl0TC0tX2xGWG55OXh0dzY3QWtqS05TbUY5SXhzSG1sYjNzeG9FNWNIb1pmMkE5UDlsbmtTd1lGYkZjLX…

Google News hu, 13 Aug 2026

Merit Medical Systems Stock Climbs 25% On A 14-Day Winning Streak - Trefis

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNd1ZYVkRiVHVJZ001cElETVRXa3ZfT1F2eDVzNHVic1lpT2I1RnR4OGZrRjg4T3VFUGlLZkJINndCSkVKUzBhS1o5TTFnNzQ4ZnhwQU1WZ0F6b3J6Mk14SkZKektwNFozMXA3aUFkaTR2TzBsNTZZREp6YXF5Rk5BaTNHek5KSmFMc3dZZS…

MMSI — Frequently Asked Questions

What is the current share price of Merit Medical Systems, Inc. (MMSI)?

As of 2026-09-07 16:24 PDT, Merit Medical Systems, Inc. (MMSI) trades at $89.60 on NasdaqGS. Its 52-week range is $60.31 to $93.18.

What is the market capitalisation of MMSI?

Merit Medical Systems, Inc. (MMSI) has a market capitalisation of $5.35B on NasdaqGS.

What is the P/E ratio of MMSI?

MMSI trades at a trailing price-to-earnings (P/E) ratio of 36.87. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.27.

What is the return on equity (ROE) of MMSI?

MMSI has a return on equity (ROE) of 9.19%. Its return on capital employed (ROCE) is 7.55%.

Is MMSI a good stock to buy?

This page provides a data-driven analysis of Merit Medical Systems, Inc. (MMSI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Merit Medical Systems, Inc. MMSI R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

MMSI vs. WST: Which Stock Should Value Investors Buy Now? - Eastern Progress

Merit Medical is scheduled for investor events in Boston, New York and online - Stock Titan

COO vs. MMSI: Which Stock Is the Better Value Option? - Yahoo Finance

Here's Why You Should Add Merit Medical Stock to Your Portfolio Now - TradingView

3 Overrated Stocks with Warning Signs - StockStory

Merit Medical Systems Stock Climbs 25% On A 14-Day Winning Streak - Trefis

MMSI — Frequently Asked Questions

What is the current share price of Merit Medical Systems, Inc. (MMSI)?

What is the market capitalisation of MMSI?

What is the P/E ratio of MMSI?

What is the return on equity (ROE) of MMSI?

Is MMSI a good stock to buy?

Explore More